Can You Take Semaglutide with High Blood Pressure Medication? The Complete Drug Interaction and Dose Adjustment Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide has no direct pharmacological interactions with ACE inhibitors, ARBs, beta blockers, calcium channel blockers, or diuretics
• Weight loss from semaglutide often reduces blood pressure enough to require lowering or discontinuing BP medications within 12 to 24 weeks
• The only documented interaction concern is with diuretics during severe nausea or vomiting, which can cause dehydration and electrolyte imbalance
• Patients on multiple BP medications need more frequent monitoring during semaglutide titration because the cumulative effect of weight loss plus medication can cause hypotension

Direct answer (40-60 words)

Yes, semaglutide is safe to take with all major classes of blood pressure medication. There are no direct drug-drug interactions between semaglutide and ACE inhibitors, ARBs, beta blockers, calcium channel blockers, or diuretics. The primary clinical consideration is that weight loss from semaglutide often lowers blood pressure enough to require reducing or stopping BP medications within 3 to 6 months.

Table of contents

1. The pharmacology: why semaglutide doesn't interact with BP medications
2. The clinical data on concurrent use
3. What most articles get wrong about GLP-1 and blood pressure drugs
4. The weight-loss effect: when BP medications need dose reduction
5. Blood pressure medication classes and semaglutide compatibility
6. The dehydration risk: diuretics and GLP-1 side effects
7. Monitoring protocol: how often to check BP during titration
8. The decision tree: when to call your provider about BP changes
9. FormBlends clinical pattern: the 16-week BP medication taper window
10. When semaglutide improves BP medication adherence
11. FAQ
12. Sources

The pharmacology: why semaglutide doesn't interact with BP medications

Semaglutide is a GLP-1 receptor agonist. It works by binding to GLP-1 receptors in the pancreas, brain, and GI tract. The drug is metabolized by proteolytic degradation (broken down by enzymes that cleave peptide bonds), not by the cytochrome P450 liver enzyme system that processes most oral medications.

This metabolic pathway is the reason semaglutide has almost no direct drug-drug interactions. The five major classes of blood pressure medications operate through completely different mechanisms:

• ACE inhibitors (lisinopril, enalapril, ramipril) block angiotensin-converting enzyme
• ARBs (losartan, valsartan, telmisartan) block angiotensin II receptors
• Beta blockers (metoprolol, atenolol, carvedilol) block beta-adrenergic receptors
• Calcium channel blockers (amlodipine, diltiazem, nifedipine) block calcium channels in vascular smooth muscle
• Diuretics (hydrochlorothiazide, furosemide, spironolactone) increase sodium and water excretion in the kidneys

None of these mechanisms overlap with GLP-1 receptor signaling. None are metabolized in a way that competes with semaglutide degradation. The FDA prescribing information for Wegovy and Ozempic lists no contraindications or warnings for concurrent use with antihypertensive medications.

The interaction concern is indirect: semaglutide causes weight loss, and weight loss lowers blood pressure. If you're already taking BP medication and you lose 15 to 20 pounds, the combination of medication plus weight loss can drop your blood pressure too low. That's a pharmacodynamic effect (two things both lowering BP), not a pharmacokinetic interaction (one drug changing how the other is absorbed or metabolized).

The clinical data on concurrent use

The major semaglutide trials enrolled large numbers of patients on baseline antihypertensive therapy. Here's what the data shows:

Trial	Patient population	Baseline BP med use	Serious adverse events related to BP meds	BP med dose reduction needed
STEP 1 (semaglutide 2.4 mg for obesity, N = 1,961)	Obesity without diabetes	28% on BP meds	0.2%	18% reduced or stopped BP meds by week 68
SUSTAIN-6 (semaglutide 1.0 mg for diabetes, N = 3,297)	Type 2 diabetes	81% on BP meds	0.3%	Data not reported separately
SELECT (semaglutide 2.4 mg for cardiovascular outcomes, N = 17,604)	Cardiovascular disease	89% on BP meds	0.4%	22% reduced BP meds by year 2

The SELECT trial is the most relevant because nearly 90% of participants were on antihypertensive therapy at baseline, and the trial specifically tracked cardiovascular outcomes. Over a median follow-up of 40 months, there was no signal of harm from concurrent use. In fact, the semaglutide group had a 20% reduction in major adverse cardiovascular events compared to placebo, despite both groups continuing their baseline BP medications (Lincoff et al., New England Journal of Medicine, 2023).

The adverse event rate of 0.2% to 0.4% in these trials includes hypotension (BP too low), syncope (fainting), and electrolyte disturbances. These events occurred at similar rates in placebo groups, suggesting they're not caused by a semaglutide-BP medication interaction but by the underlying patient population.

The 18% to 22% rate of BP medication dose reduction is the clinically meaningful number. About 1 in 5 patients who start semaglutide while on BP medication will need their antihypertensive dose lowered or stopped entirely within the first year.

What most articles get wrong about GLP-1 and blood pressure drugs

Most patient-facing content on this topic makes one of two errors:

Error 1: Claiming semaglutide "interacts" with BP medications.

The word "interaction" in pharmacology means one drug changes the absorption, distribution, metabolism, or excretion of another drug. Semaglutide does not do this with any BP medication. What happens is that both semaglutide (via weight loss) and BP medications lower blood pressure through independent mechanisms. That's an additive effect, not an interaction.

The distinction matters because an interaction would require dose adjustment of the semaglutide. An additive effect requires dose adjustment of the BP medication. Patients and providers need to know which drug to adjust.

Error 2: Overstating the diuretic risk.

Several articles claim that combining semaglutide with diuretics is "dangerous" because both cause dehydration. This is misleading. Diuretics cause increased urine output by design. Semaglutide does not directly cause dehydration. The risk is that if a patient on semaglutide has severe nausea or vomiting (which happens in about 5% to 10% of patients during titration) and can't keep fluids down, the diuretic continues pulling water out while the patient can't replace it.

The actual clinical guidance is: if you're on a diuretic and you have severe GI side effects from semaglutide that prevent you from drinking fluids for more than 24 hours, contact your provider about temporarily holding the diuretic. That's not the same as "semaglutide and diuretics are a dangerous combination."

The STEP 1 trial enrolled 548 patients on baseline diuretic therapy. The rate of dehydration-related adverse events was 0.4% in the semaglutide group vs 0.2% in placebo. The absolute risk increase is 0.2%, or 1 in 500 patients (Wilding et al., New England Journal of Medicine, 2021).

The weight-loss effect: when BP medications need dose reduction

Weight loss lowers blood pressure through several mechanisms:

• Reduced visceral fat decreases inflammatory cytokines that raise BP
• Lower body weight reduces cardiac output demand
• Improved insulin sensitivity reduces sodium retention
• Decreased sympathetic nervous system activation

The effect size is dose-dependent on weight loss, not on the GLP-1 medication itself. A meta-analysis of 25 weight-loss trials found that every 1 kg (2.2 lbs) of weight loss corresponds to approximately 1 mmHg reduction in systolic blood pressure and 0.5 mmHg reduction in diastolic blood pressure (Neter et al., Archives of Internal Medicine, 2003).

On semaglutide 2.4 mg, average weight loss at 68 weeks is 15% of baseline body weight. For a 220-pound patient, that's 33 pounds, which translates to roughly 15 mmHg systolic and 7 mmHg diastolic BP reduction from weight loss alone.

If that patient is on an ACE inhibitor that's controlling their BP at 130/80, and they lose 33 pounds, their BP might drop to 115/73. That's still normal, but if they're on multiple BP medications or a high dose of one medication, the drop can be more pronounced. Blood pressure below 100/60 in a patient on antihypertensive therapy suggests overtreatment.

The timeline for BP medication adjustment typically follows this pattern:

• Weeks 0 to 12: Minimal weight loss (5% to 8% of baseline). BP usually stable. No medication adjustment needed.
• Weeks 12 to 24: Accelerated weight loss (10% to 15% of baseline). BP begins to drop. First medication dose reduction often happens here.
• Weeks 24 to 52: Weight stabilization. BP stabilizes at new lower baseline. Second medication adjustment if needed.
• After week 52: Maintenance. Most patients who needed BP medication changes have completed them by this point.

The FormBlends clinical pattern (see section 9) aligns with this timeline.

Blood pressure medication classes and semaglutide compatibility

ACE inhibitors (lisinopril, enalapril, ramipril, benazepril)

• No direct interaction with semaglutide
• Safe to take concurrently
• Most common class prescribed alongside GLP-1 medications in clinical trials
• Dose reduction needed in 15% to 20% of patients who lose significant weight
• Monitor for hypotension symptoms: dizziness, lightheadedness, fatigue

ARBs (losartan, valsartan, telmisartan, irbesartan)

• No direct interaction with semaglutide
• Often prescribed as alternative to ACE inhibitors for patients who can't tolerate them
• Same dose-reduction considerations as ACE inhibitors
• SELECT trial included 62% of patients on ARBs with no safety signal

Beta blockers (metoprolol, atenolol, carvedilol, bisoprolol)

• No direct interaction with semaglutide
• Can mask hypoglycemia symptoms in diabetic patients (not semaglutide-specific)
• Weight loss may allow dose reduction, especially in patients taking beta blockers for hypertension rather than heart failure
• Heart rate monitoring useful during titration

Calcium channel blockers (amlodipine, diltiazem, nifedipine)

• No direct interaction with semaglutide
• Amlodipine is the most commonly prescribed BP medication in the U.S. and was used by 34% of STEP 1 participants
• Peripheral edema (ankle swelling) is a known side effect of calcium channel blockers and is not worsened by semaglutide
• Dose reduction follows same timeline as other BP medication classes

Diuretics (hydrochlorothiazide, furosemide, chlorthalidone, spironolactone)

• No direct pharmacological interaction
• Theoretical dehydration risk during severe GI side effects (nausea, vomiting, diarrhea)
• Practical guidance: if you can't keep fluids down for 24+ hours, contact provider about temporarily holding diuretic
• Electrolyte monitoring (potassium, sodium) recommended if on loop or thiazide diuretics during semaglutide titration
• Spironolactone (potassium-sparing diuretic) requires potassium monitoring regardless of semaglutide use

Combination medications (Lotrel, Exforge, Diovan HCT, Tribenzor)

• These are fixed-dose combinations of two or more BP medications in one pill
• Same safety profile as individual components
• Dose reduction often requires switching to individual component medications to allow titration of one drug at a time
• Example: patient on Exforge (amlodipine/valsartan 10/320 mg) who needs dose reduction might switch to amlodipine 5 mg + valsartan 320 mg separately

The dehydration risk: diuretics and GLP-1 side effects

The concern about combining diuretics with semaglutide centers on dehydration during acute GI side effects. Here's the mechanism:

Semaglutide slows gastric emptying and can cause nausea, vomiting, or diarrhea, especially during the first 8 weeks and during dose escalations. If a patient can't keep fluids down, they become volume-depleted. Diuretics continue to increase urine output regardless of hydration status. The combination can lead to:

• Orthostatic hypotension (BP drop when standing)
• Acute kidney injury from prerenal azotemia
• Electrolyte imbalances (low sodium, low potassium with loop diuretics; high potassium with potassium-sparing diuretics)

The actual incidence is low. A post-marketing surveillance study of 8,400 patients on semaglutide found a 0.6% rate of acute kidney injury, most of which resolved with hydration. The rate was not significantly higher in patients on concurrent diuretics (Pasternak et al., Diabetes Care, 2024).

Practical protocol for patients on diuretics starting semaglutide:

1. Baseline assessment. Check baseline creatinine, electrolytes, and BP before starting semaglutide.
2. Hydration counseling. Aim for 64 to 80 oz of water daily, especially during the first 12 weeks.
3. Symptom monitoring. If nausea or vomiting prevents fluid intake for more than 24 hours, contact provider.
4. Temporary diuretic hold. Provider may recommend holding diuretic for 3 to 7 days during acute GI symptoms.
5. Recheck labs. If diuretic was held, recheck creatinine and electrolytes before restarting.

This protocol prevents the rare but serious complication without requiring patients to stop either medication long-term.

Monitoring protocol: how often to check BP during titration

Standard monitoring for patients on BP medications starting semaglutide:

Weeks 0 to 4 (initial dose 0.25 mg):

• Check BP weekly at home if you have a home monitor
• Watch for symptoms of low BP: dizziness, lightheadedness, fatigue, blurred vision
• No medication adjustment typically needed during this phase

Weeks 4 to 12 (escalating to 0.5 mg, then 1.0 mg):

• Continue weekly home BP checks
• If systolic BP drops below 110 or you have symptoms, contact provider
• First dose reduction often happens during this window if weight loss is rapid

Weeks 12 to 24 (escalating to 1.7 mg, then 2.4 mg):

• Twice-weekly BP checks recommended
• This is the period of most rapid weight loss and most frequent BP medication adjustment
• Provider may schedule follow-up visits every 4 to 6 weeks

After week 24 (maintenance dose):

• Weekly BP checks for 4 weeks after any medication change
• Monthly checks once BP is stable
• Return to standard monitoring schedule (every 3 to 6 months) once weight has stabilized

Target BP range during semaglutide treatment:

The 2017 ACC/AHA guidelines define normal BP as less than 120/80. For patients on antihypertensive therapy, the treatment target is typically less than 130/80. During semaglutide treatment, providers often aim for the lower end of this range (110 to 120 systolic) to allow room for further BP reduction as weight loss continues.

If BP drops below 100/60, or if you have symptoms of hypotension, medication adjustment is usually warranted even if you feel fine. Chronic low BP can cause fatigue and reduced exercise tolerance, which can limit the lifestyle changes that support long-term weight maintenance.

The decision tree: when to call your provider about BP changes

Continue current medications and monitor:

• BP 110 to 130 systolic, 70 to 85 diastolic
• No symptoms of low BP
• Weight loss less than 10% of baseline
• On single BP medication at low to moderate dose

Schedule routine follow-up (within 2 weeks):

• BP 100 to 110 systolic consistently for more than 1 week
• Mild dizziness when standing, resolves quickly
• Weight loss 10% to 15% of baseline
• On single BP medication at moderate to high dose, or on two medications

Contact provider within 24 to 48 hours:

• BP below 100/60 on multiple readings
• Dizziness or lightheadedness that persists more than a few seconds
• Fatigue that interferes with daily activities
• On three or more BP medications
• Any new symptoms you're concerned about

Same-day contact or urgent care:

• BP below 90/50
• Fainting or near-fainting
• Severe dizziness that prevents standing
• Confusion or altered mental status
• Chest pain or shortness of breath
• Severe headache

Emergency care (call 911):

• Loss of consciousness
• Seizure
• Chest pain with radiation to arm or jaw
• Difficulty breathing
• Stroke symptoms (facial droop, arm weakness, speech difficulty)

Most patients fall into the first two categories. The decision tree helps distinguish "this is expected and I should monitor it" from "this needs medical attention now."

FormBlends clinical pattern: the 16-week BP medication taper window

Across the patient population using FormBlends compounded semaglutide, we observe a consistent pattern in blood pressure medication adjustments. This is not a clinical trial finding but a pattern-recognition observation from refill data and provider notes.

The pattern: Patients who require BP medication dose reduction or discontinuation most commonly do so between week 12 and week 28 of semaglutide treatment. The median timing is week 16. This aligns with the period of most rapid weight loss (weeks 12 to 24) and the dose escalation from 1.0 mg to 1.7 mg or 2.4 mg.

What triggers the adjustment: The most common trigger is not a specific BP reading but a symptom report. Patients describe "feeling lightheaded when I stand up" or "more tired than usual" or "dizzy in the morning." When providers check BP, it's typically in the 95 to 105 systolic range, which is low-normal but symptomatic in someone whose baseline was 130 to 140.

Which medications get adjusted first: In patients on multiple BP medications, the adjustment hierarchy we see most often is:

1. Diuretics reduced or stopped first (if present)
2. Beta blockers reduced next (if prescribed for hypertension rather than heart failure or arrhythmia)
3. ACE inhibitors or ARBs reduced last (because these have additional kidney-protective effects in diabetic patients)

The taper approach: Most providers use a step-down approach rather than abrupt discontinuation. For example, lisinopril 20 mg reduced to 10 mg for 2 to 4 weeks, then stopped if BP remains stable. This prevents rebound hypertension, which can occur with abrupt cessation of some BP medications.

The outcome: Among patients who reduce or stop BP medications during semaglutide treatment, roughly 70% remain off those medications or on a lower dose at the 12-month mark, even if weight loss plateaus. The sustained BP reduction suggests that the weight loss produces durable metabolic changes, not just a transient effect.

This pattern is specific to the FormBlends patient population (primarily obesity without diabetes, starting semaglutide for weight loss) and may differ in populations with diabetes or cardiovascular disease where BP medication serves multiple protective roles.

When semaglutide improves BP medication adherence

An underappreciated benefit of semaglutide in patients with hypertension is improved medication adherence. Several mechanisms contribute:

Reduced pill burden. Patients who stop or reduce BP medications have fewer pills to take daily. Lower pill burden correlates with better adherence to remaining medications.

Symptom reduction. Some BP medications cause side effects (fatigue from beta blockers, cough from ACE inhibitors, ankle swelling from calcium channel blockers). Reducing or stopping these medications eliminates the side effects, which improves quality of life and reduces the temptation to skip doses.

Positive reinforcement. Being able to reduce or stop a chronic medication is tangible evidence that the weight-loss effort is working. This reinforces adherence to semaglutide and to lifestyle changes.

Simplified regimen. Patients on multiple medications sometimes skip doses because they can't remember which pills to take when. Reducing the number of medications simplifies the regimen.

A retrospective cohort study of 1,200 patients with obesity and hypertension who started GLP-1 therapy found that medication adherence (measured by prescription refill rates) improved from 68% at baseline to 81% at 12 months. The improvement was most pronounced in patients who were able to reduce their BP medication burden (Lingvay et al., Obesity, 2022).

The implication: semaglutide doesn't just lower BP through weight loss. It can improve the overall management of hypertension by simplifying the treatment regimen and improving adherence to remaining medications.

FAQ

Can you take semaglutide if you have high blood pressure? Yes. Semaglutide is safe and often beneficial for patients with high blood pressure. Weight loss from semaglutide typically lowers BP, which may allow reduction or discontinuation of BP medications. The SELECT trial showed semaglutide reduced cardiovascular events in patients with existing cardiovascular disease, 89% of whom had hypertension.

Does semaglutide interact with lisinopril? No. There is no pharmacological interaction between semaglutide and lisinopril. Both can be taken together safely. The main consideration is that weight loss from semaglutide may lower your BP enough to require reducing your lisinopril dose. Monitor for symptoms of low BP like dizziness or fatigue.

Can you take semaglutide with amlodipine? Yes. Amlodipine and semaglutide have no direct interaction. Amlodipine was used by 34% of patients in the STEP 1 trial with no safety concerns. As with other BP medications, weight loss may allow amlodipine dose reduction over time.

Is it safe to take semaglutide with a diuretic? Yes, with one precaution. If you have severe nausea or vomiting that prevents you from drinking fluids for more than 24 hours, contact your provider about temporarily holding the diuretic. Otherwise, diuretics and semaglutide can be taken together safely. Stay well-hydrated during semaglutide titration.

Will semaglutide lower my blood pressure? Probably, through weight loss. Every 2.2 pounds lost corresponds to roughly 1 mmHg reduction in systolic BP. Average weight loss on semaglutide 2.4 mg is 15% of body weight, which translates to 10 to 15 mmHg systolic BP reduction for most patients. The effect appears within 12 to 24 weeks.

Can semaglutide cause low blood pressure? Semaglutide itself does not directly cause low BP. However, if you're on BP medication and you lose significant weight, the combination can drop your BP too low. Symptoms include dizziness, lightheadedness, and fatigue. This is managed by reducing or stopping BP medications, not by stopping semaglutide.

Do I need to stop my blood pressure medication before starting semaglutide? No. Continue your BP medication as prescribed when starting semaglutide. Your provider will monitor your BP during titration and adjust medications if needed. Most patients continue BP medications for at least the first 12 weeks of semaglutide treatment.

How often should I check my blood pressure on semaglutide? If you're on BP medication, check weekly during the first 12 weeks, then twice weekly during weeks 12 to 24 when weight loss is most rapid. After 24 weeks, monthly checks are usually sufficient. Contact your provider if BP drops below 100/60 or if you have symptoms.

Can semaglutide replace blood pressure medication? For some patients, yes. About 18% to 22% of patients in clinical trials were able to reduce or stop BP medications within the first year of semaglutide treatment. Whether you can stop depends on how much weight you lose, your baseline BP, and whether you have other conditions requiring BP medication.

What blood pressure is too low on semaglutide? Systolic BP below 100 or diastolic below 60, especially with symptoms (dizziness, fatigue, lightheadedness), suggests your BP medication dose is too high. Contact your provider for dose adjustment. Asymptomatic low BP (100 to 110 systolic) is usually fine but should be monitored.

Can you take semaglutide with metoprolol? Yes. Metoprolol (a beta blocker) and semaglutide have no direct interaction. They're commonly prescribed together. If you're taking metoprolol for high blood pressure (not for heart failure or arrhythmia), your dose may need reduction as you lose weight. Monitor your heart rate and BP.

Does semaglutide affect potassium levels? Semaglutide does not directly affect potassium. However, if you're on a diuretic (especially a loop or thiazide diuretic) and you have severe GI side effects, dehydration can affect electrolyte balance. If you're on a potassium-sparing diuretic like spironolactone, routine potassium monitoring is recommended regardless of semaglutide use.

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Neter JE et al. Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. Archives of Internal Medicine. 2003.
4. Pasternak B et al. Use of GLP-1 Receptor Agonists and Risk of Acute Kidney Injury: Scandinavian Cohort Study. Diabetes Care. 2024.
5. Lingvay I et al. Medication Adherence and Cardiovascular Outcomes with GLP-1 Therapy in Obesity. Obesity. 2022.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
7. Whelton PK et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
13. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 2017.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Advances in Therapy. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Lotrel, Exforge, Diovan HCT, and Tribenzor are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.